Atezolizumab for Previously Treated Non-Small Cell Lung Cancer: Julien Mazières, MD, PhD

For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respiratory Medicine at Toulouse University Hospital, discusses his collaborative research finding that atezolizumab increases long-term overall survival compared with docetaxel, regardless of histology, subsequent immunotherapy, and programmed death ligand...
Continue reading

Paul Sargos, MD on Adjuvant RT versus Salvage RT for Prostate Cancer

Results of a new study presented at American Society of Radiation Oncology (ASTRO) 2020 reveal that adjuvant radiotherapy (aRT) significantly increased the risk of late toxicity compared with salvage radiotherapy (sRT). Lead author of the study, Paul Sargos, MD, discusses the significance of these results in addition to advice for community oncologists treating this patient population in this interview with i3 Health. What was the rationale for this study? Paul Sargos, MD: To understand the impo...
Continue reading

Nivolumab/Ipilimumab for Malignant Pleural Mesothelioma: Paul Baas, MD, PhD

The FDA recently approved nivolumab/ipilimumab for the first-line treatment of malignant pleural mesothelioma, marking the second FDA approval for this condition and the first approval in the past 16 years. In this interview, Paul Baas, MD, PhD, principal investigator of the CheckMate 743 trial (NCT02899299), on which the approval was based, speaks with Oncology Data Advisor about the benefits and tolerability of nivolumab/ipilimumab, ongoing research advances in the treatment of malignant pleur...
Continue reading

Ming Shi, MD, PhD: HAIC/FOLFOX Effective for Hepatocellular Carcinoma

A recent study presented by Ming Shi, MD, PhD and colleagues at ESMO Virtual Congress 2020 found that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) yield more effective results in patients with unresectable hepatocellular carcinoma (HCC) compared with transarterial chemoembolization (TACE). In an interview with i3 Health, Dr. Shi shares insights about the significance of these results, as well as the future of treatment for HCC, and advice ...
Continue reading

Antifungal Prophylaxis for Hematologic Malignancies: Yuan Wan, MD, PhD

While antifungal prophylaxis can effectively prevent invasive fungal infections in patients with hematologic diseases, there is no consensus on which prophylactic agents provide the greatest benefit for different patient populations. In a meta-analysis recently published in JAMA Network Open, a team of researchers found that among antifungal prophylactic agents, posaconazole may be the best option for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), while voriconazo...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.